Medicago Inc (Medicago) is a clinical-stage biotechnology company. The Company is focused on the development of vaccines using its Virus-Like Particules (VLPs) and manufacturing technologies. Medicago's VLP manufacturing technology is based on a transient expression system, which produces recombinant vaccine antigens in non-transgenic plants. Medicago operates a 24,000-square-foot production facility located in the Technology Park in Quebec City, Canada. This facility includes a Biosafety level 2 greenhouse, an extraction and purification unit, and is cGMP compliant. The Company's products include Pandemic flu vaccine and Seasonal flu vaccine. Medicago U.S.A is a wholly owned subsidiary of Medicago.
|Headquarters||Bureau 600, 1020, route de l'glise|
QUEBEC, QC, Canada G1V 3V9
|Independent Chairman of the Board||Randal Chase|
|President, Chief Executive Officer, Director||Andrew Sheldon|
|Chief Financial Officer, Vice President||Pierre Labbe|
|Executive Vice President - Operations||Michael Wanner|
|Vice President - Quality Assurance and Quality Control||Brigitte Barbeau|
With TD Waterhouse, you have access to the industry's leading selection of independent research reports from providers such as TDSI, TD Securities, S&P, INK and Argus.
|Shares Out.||254.7M||Book Value||$0.15|
|Annual Dividend Rate||$0.00||Price/Sales (TTM)||34.3|
|Ex-Div Date||1/1/01||P/Cash Flow (TTM)||--|
|Pay Date||1/1/01||Operating Margin||-532.80%|
*GAAP = prior to non-GAAP analyst adjusted earnings.